6346-05-0

Basic information

• Product Name: 3-Benzyloxy-4-methoxybenzaldehyde
• Synonyms: AKOS BBS-00003177;O-BENZYLISOVANILLIN;Benzaldehyde, 4-methoxy-3-(phenylmethoxy)-;3-Benzyloxy-p-anisaldehyde;4-Methoxy-3-(benzyloxy)benzaldehyde;3-Benzyloxy-4-methoxybenzaldehyde,98%;3-Benzyloxy-4-methox;Isovanillin benzyl ether
• CAS NO: 6346-05-0
• Molecular Formula: C₁₅H₁₄O₃
• Molecular Weight: 242.27
• EINECS: 228-752-7
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Aromatics;Aldehydes;C10 to C21;Carbonyl Compounds
• Mol File: 6346-05-0.mol
• Article Data: 133

Chemical Properties

• Melting Point: 61-64 °C(lit.)
• Boiling Point: 120 °C / 5mmHg
• Appearance: /
• Density: 1.1515 (rough estimate)
• Refractive Index: 1.5570 (estimate)
• Storage Temp.: Store below +30°C.
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• Sensitive: Air Sensitive
• BRN: 794627
• CAS DataBase Reference: 3-Benzyloxy-4-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzyloxy-4-methoxybenzaldehyde(6346-05-0)
• EPA Substance Registry System: 3-Benzyloxy-4-methoxybenzaldehyde(6346-05-0)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 6346-05-0(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

3-Benzyloxy-4-methoxybenzaldehyde was used in the synthesis of (+)-9-benzyloxy-α-dihydrotetrabenazine. It was also used in total synthesis of (-)-galipeine.

InChI:InChI=1/C15H14O3/c1-17-14-8-7-13(10-16)9-15(14)18-11-12-5-3-2-4-6-12/h2-10H,11H2,1H3

Upstream product

• 621-59-0 isovanillin 
• 100-44-7 benzyl chloride 
• 38849-38-6 3-(benzyloxy)-2-bromo-4-methoxybenzaldehyde 
• 6272-38-4 O-benzylcatechol 
• 100-39-0 benzyl bromide 
• 584-08-7 potassium carbonate 
• 6100-74-9 3-hydroxy-4-methoxyacetophenone 
• 1860-60-2 3-benzyloxy-4-methoxy-benzyl alcohol 
• 83088-21-5 3-(β-methoxyethoxymethyloxy)-4-methoxybenzaldehyde 
• 55667-17-9 3-benzyloxy-4-methoxybenzaldehyde oxime 
• 100-51-6 benzyl alcohol 
• 50773-56-3 3-benzyloxy-4-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 

Downstream Products

• 64518-70-3 4-(3-Benzyloxy-4-methoxy-benzylamino)-benzoic acid 
• 124465-47-0 2-benzoyloxy-2-(3'-benzyloxy-4'-methoxy)acetonitrile 
• 50773-56-3 3-benzyloxy-4-hydroxybenzaldehyde 
• 71146-42-4 Acetic acid 1-(3-benzyloxy-4-methoxy-phenyl)-2-isocyano-ethyl ester 
• 71146-41-3 1-(3-benzyloxy-4-methoxy-phenyl)-2-isocyano-ethanol 
• 63909-29-5 3-benzyloxy-4-methoxy-β-nitrostyrene 
• 40914-18-9 3-(benzyloxy)-4-methoxyphenyl formate 
• 27065-64-1 (4-Benzyloxy-2-{[1-(3-benzyloxy-4-methoxy-phenyl)-meth-(E)-ylidene]-amino}-5-methoxy-phenyl)-acetic acid ethyl ester 
• 63368-30-9 4-Chlor-3'-benzyloxy-4'-methoxystilben 
• 63368-25-2 3-Methyl-3'-benzyloxy-4'-methoxystilben 
• 63368-29-6 4-Fluor-3'-benzyloxy-4'-methoxystilben 
• 63368-28-5 4-Methoxycarbonyl-3'-benzyloxy-4'-methoxystilben 
• 63368-17-2 4,3'-Di(benzyloxy)-4'-methoxystilben 
• 63368-15-0 2,3'-Di(benzyloxy)-4'-methoxystilben 

Relevant articles and documents

Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents.

Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors

Vesicular monoamine transporter 2 (VMAT2) is essential for synaptic transmission of all biogenic amines in the brain including serotonin, norepinephrine, histamine, and dopamine (DA). Given its crucial role in the neurophysiology and pharmacology of the central nervous system, VMAT2 is recognized as an important therapeutic target for various neurological disorders such as tardive dyskinesia (TD). Here, a novel series of dihydrotetrabenazine derivative analogs were designed and synthesized to evaluate their effects on [3H]dihydrotetrabenazine (DTBZ) binding and [3H]DA uptake at VMAT2. Of these analogs, compound 13e showed a high binding affinity for VMAT2 (IC50 = 5.13 ± 0.16 nM) with excellent inhibition of [3H]DA uptake (IC50 = 6.04 ± 0.03 nM) in striatal synaptosomes. In human liver microsomes, 13e was more stable (T1/2 = 161.2 min) than other reported VMAT2 inhibitors such as DTBZ (T1/2 = 119.5 min). In addition, 13e effectively inhibited the spontaneous locomotor activity (percent inhibition at 3 μmol/kg = 64.7%) in Sprague-Dawley rats. Taken together, our results indicate that 13e might be a promising lead compound for the development of novel treatments of TD.

Synthesis and characterisation of novel tricyclic and tetracyclic furoindoles: Biological evaluation as SAHA enhancer against neuroblastoma and breast cancer cells

The dihydropyranoindole structures were previously identified as promising scaffolds for improving the anti-cancer activity of histone deacetylase inhibitors. This work describes the synthesis of related furoindoles and their ability to synergize with suberoylanilide hydroxamic acid (SAHA) against neuroblastoma and breast cancer cells. The nucleophilic substitution of hydroxyin-dole methyl esters with α-haloketones yielded the corresponding arylether ketones, which were subsequently cyclized to tricyclic and tetracyclic furoindoles. The furoindoles showed promising individual cytotoxic efficiency against breast cancer cells, as well as decent SAHA enhancement against cancer cells in select cases. Interestingly, the best IC50 value was obtained with the non-cyclized intermediate.